Navigation Links
Trovagene, Inc. Announces Second Quarter 2013 Earnings

SAN DIEGO, Aug. 14, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and the six months ended June 30, 2013.


Second Quarter 2013 Financial ResultsFor the three months ended June 30, 2013, Trovagene reported a net loss of $5.3 million, or $0.34 per share, as compared to a net loss of $3.4 million, or $0.28 per share, for the three months ended June 30, 2012. The increase in net loss is primarily due to an increase in the total operating expenses of $1.1 million, or $0.07 per share, as well as an increase in the change in fair value of derivative instruments related to warrants of $0.7 million, $0.04 per share, during the second quarter of 2013 as compared to the prior year comparable period.

First Half Financial ResultsNet loss for the six months ended June 30, 2013 is $6.4 million or $0.41 per share, as compared to a loss of $4.6 million, or $0.40 per share for the six months ended June 30, 2012. The increase in net loss is primarily attributable to an increase in the total operating expenses of $2.5 million, or $0.16 per share, which was offset by a decrease in the change in fair value of derivative instruments related to warrants of $0.6 million, $0.04 per share, as compared to the prior year comparable period.

Cash and Cash EquivalentsTrovagene had cash and cash equivalents of $8.3 million at June 30, 2013, as compared to $10.8 million at December 31, 2012. The Company completed a $15 million direct registered offering on July 31, 2013, and has approximately $29 million in cash and cash equivalents as of August 9, 2013.

Review of 2013 Announcements Demonstrate Progress in Development Programs

  • Issuance of broad microRNA patent covering methods of detecting and quantitating cell-free microRNA in urine and blood.
  • Validated urine-based cancer detection technology and developed an ultra-sensitive cell-free DNA assay initially confirmed for the detection of the BRAF mutation
  • Launched HPV-HR assay, a urine-base molecular human papillomavirus (HPV) test in 2013.
  • Extended planned offering of urine-based oncogene mutation tests to include a test for the detection of a specific p53 mutation and a specific double mutation in the hepatitis B virus.
  • Expanded clinical collaboration with the University of Texas MD Anderson Cancer Center to include the detection of transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers.
  • About Trovagene, Inc.Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.

    (Financial Information to Follow)

     ContactTrovagene, Inc.FinancialInvestor RelationsStephen Zaniboni

    Chief Financial OfficerAmy Caterina

    Investor RelationsTrovagene, Inc.Trovagene, Trovagene, Inc. and Subsidiaries(A Development Stage Company)Selected Financial InformationConsolidated Condensed Statements of Operations and Comprehensive Loss(in thousands, except for per share amounts)Three Months EndedJune 30,Six Months EndedJune 30,2013201220132012(Unaudited)(Unaudited)Revenues$




    76Operating expenses:Research and development 9444771,746815General and administrative 1,4798103,1861,637Total operating expenses2,4231,2874,9322,452Operating loss(2,374)(1,246)(4,764)(2,376)Interest expense(1)-(1)-Change in fair value of derivative instruments - warrants(2,895)(2,181)(1,616)(2,213)Net loss and comprehensive loss$




    (4,589)Preferred stock dividend(9)(9)(15)(19)Net loss and comprehensive loss available to common stockholders$






    $(4,608)Basic and diluted net loss per share$






    $(0.40)Weighted average shares outstanding- basic and diluted15,584 

    12,08615,54711,544 Trovagene, Inc. and Subsidiaries(A Development Stage Company)Consolidated Condensed Balance Sheet Information(in thousands)June 30,
    2013December 31,
    2012(Unaudited) Cash and cash equivalents$


    10,820Other assets752590Property and equipment, net571255Total assets$


    11,665Current portion of long term debt$


    -Accounts payable, accrued expenses and other liabilities1,385730Long-term debt, less current portion252-Derivative financial instruments10,3828,766Stockholders' (deficiency) equity (2,457)2,169Total liabilities and stockholders' (deficiency) equity$



    SOURCE Trovagene, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Trovagene, Inc. Announces Closing of $15 Million Registered Direct Offering of Common Stock
    2. Trovagene, Inc., Announces Fourth Quarter and Year End 2012 Earnings
    3. Trovagene, Inc., Announces Third Quarter and Year to Date Earnings, Provides Milestone Update
    4. Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
    5. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
    6. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
    7. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
    8. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
    9. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
    10. Accelerate Diagnostics Announces Final Results of Rights Offering
    11. Vasomedical Announces Financial Results for the Second Quarter of 2013
    Post Your Comments:
    (Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Advanced Wound Care Market by Type ... Ulcers), End User (In-Patient Facility, Out-Patient Facility), and Geography ... offering. --> --> ... the description, definition and forecast of the global advanced ...
    (Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
    (Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
    Breaking Medicine Technology:
    (Date:11/26/2015)... ... , ... PRMA Plastic Surgery is updating their record books yet again with ... flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... it’s an honor to have served all of these women.” , PRMA is one ...
    (Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings Final ... ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, ... giving users limitless opportunities to stylize and create designs quickly and easily, all ...
    (Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... Indosoft Inc., ... inclusion of an application server to improve system efficiency and reliability. , The new ... many of these standards, the system avoids locking itself into a specific piece of ...
    (Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
    (Date:11/25/2015)... ... ... Finnleo, a leader in the traditional and far-infrared sauna industry, announced a sale ... , For traditional saunas, Finnleo is offering 20% off all Nordic Spruce ... only European Grade A Nordic White Spruce from sustainably grown trees. Because of the ...
    Breaking Medicine News(10 mins):